Delivery Order SPE2DB20D1109-SPE2DB21FP72P
Award Date
8/5/21
Potential Completion Date
8/6/21
Potential Value
$3.2K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Cencora, Inc.
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to Amerisourcebergen Drug Corp was issued by the Defense Logistics Agency (DLA) Troop Support Medical. The $3,944.23 firm-fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a prescription medication. The contract has an ultimate completion date of October 10, 2024. Amerisourcebergen, a major pharmaceutical distributor, is the prime contractor for this award, which is part of a larger Indefinite Delivery Contract (IDC) valued at up to...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $3,363.53 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a prescription medication used to treat dry eye disease. The contract has an ultimate completion date of May 24, 2023. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which does business as Amerisourcebergen. Cencora, Inc....
This federal contract award, valued at $16,992.30, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of RESTASIS 0.05% eye emulsion. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for...
This federal contract award is to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor, to supply RESTASIS 0.05% eye emulsion to the U.S. government. The Delivery Order contract, valued at $4,363.48, was awarded on May 30, 2024 by the Defense Logistics Agency (DLA) Troop Support Medical, with a completion date of May 31, 2024. This contract is not set-aside and is awarded under Amerisourcebergen's Indefinite Delivery Contract (IDC) with the DLA, valued at...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,276.68 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a specialty medication. The contract has an ultimate completion date of November 3, 2023. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,428.66 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, with an ultimate completion date of April 14, 2022. The contract is not designated under any set-aside program. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which does business as...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,280.21 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a specialty ophthalmic medication. The contract has a completion date of June 3, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on January 3, 2022. The contract, valued at $9,109.98, is for the delivery of RESTASIS 0.05% eye emulsion. This appears to be a delivery order under a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at up to $999,999,999 and running through November 2026. The IDC serves as a primary...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,752.07 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a prescription eye medication. The contract has an ultimate completion date of May 1, 2023. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Restasis 0.05% eye emulsion. The contract, valued at $3,180.58, is a firm fixed-price delivery order with a completion date of November 26, 2021. This award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen's parent company, Cencora, Inc., with the DLA Troop Support Medical, valued at up to...